Study blood DNA markers after chemotherapy in older acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial checks a blood test called “ctDNA” (tiny pieces of leukemia DNA in blood) after chemotherapy. It may help doctors understand how well treatment is working in older adults with acute leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must agree to take part in the study (sign written consent)
- You must be male (or otherwise not be pregnant)
- You must be age 60 or older
- You must have a diagnosis of acute leukemia
- You must not be pregnant
- You must not have HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at gene patterns in people with blood cancers to better understand the disease and find possible treatments. If you are being tested for a blood cancer or have a blood cancer that came back or got worse, you may be able to join.
This study looks at whether a simple blood test can help track how well treatment is working in children with leukemia. It may help doctors understand the disease better and guide future care.
This study looks at whether a simple blood test (ctDNA test) can help track advanced breast cancer over time. It aims to see how well the test works for monitoring the disease.
This trial checks a blood test called circulating tumor DNA to help choose the best time and approach for chemotherapy after colon cancer surgery. It aims to reduce recurrence by identifying people who may benefit from treatment based on changes seen in the blood.
This trial looks at certain chemical changes in blood cells of two groups of people aged 60 or older: those having heart surgery (control group) and those with a type of blood cancer called acute myeloid leukemia (AML) who will be treated with a drug called azacitidine. The goal is to find markers that could help personalize treatment for AML in seniors.
This study looks at blood (“hematopoietic”) information in people age 60+ with relapsed B-cell non-Hodgkin lymphoma who need an additional round of treatment. It may help researchers understand changes in the body during active lymphoma therapy.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.